Business Context and Reporting Period
This Form 8-K was filed by Onconova Therapeutics, Inc. on May 31, 2016. The report details a material modification to the rights of security holders involving a reverse stock split. Note: The request metadata lists "Traws Pharma, Inc.", but the filing text explicitly identifies the registrant as Onconova Therapeutics, Inc.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure changes.
Material Changes
- Reverse Stock Split: A one-for-ten reverse stock split was effected effective 5:00 PM Eastern Time on May 31, 2016.
- Share Count Reduction: Issued and outstanding common shares decreased from approximately 27.4 million to approximately 2.7 million.
- Authorized Shares: The number of authorized common shares was reduced from 75,000,000 to 25,000,000.
- Derivative Adjustments: Per share exercise prices and share counts for outstanding options and warrants were proportionately adjusted.
- Fractional Shares: Holders entitled to fractional shares received a whole share in lieu of fractions.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the mechanics of the stock split. The company confirmed that trading will continue on the NASDAQ Capital Market under the symbol "ONTX" with a new CUSIP number (68232V 306).
Investor Verification Checklist
- Verify the new CUSIP number (68232V 306) for trading purposes.
- Confirm the adjusted share count and exercise prices for any held options or warrants.
- Check with the transfer agent (Wells Fargo Bank, N.A.) regarding the exchange of physical share certificates.
- Review the Certificate of Amendment (Exhibit 3.1) for specific legal terms of the split.